Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off.

Big pharma earnings took the spotlight, with Merck & Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) among the notable ones reporting in the week. Merck surprised the markets by announcing plans to spin-off its slow-growing Women's Health, Legacy Brands and Biosimilars business.

Here're the key biotech catalysts for the unfolding week.

Bio CEO & Investor Conference: Feb. 10-11 in New York16th Annual WORLDSymposium: Feb. 10-13 in Orlando, FloridaGuggenheim Healthcare Talks/Oncology Day: Feb. 13 in New YorkASCO 2020 Genitourinary Cancers Symposium: Feb. 13-15 in San Francisco, California

FDA's Tobacco Products Scientific Advisory Committee is scheduled to meet Friday to discuss the modified risk tobacco product applications submitted by 22nd Century Group Inc (NYSE: XXII) for VLN King and VLN Menthol King combusted, filtered cigarettes. The company projectsthese tobacco products to be "very low nicotine content" cigarettes.

Avrobio Inc (NASDAQ: AVRO) will present at the 2020 WORLDSymposium updates for its investigational programs in Fabry disease and cystinosis as well as data from the first clinical use of its plato gene therapy platform. At an analyst and investor event scheduled for Monday, the company will present updates on Phase 1/2 clinical trial of AVR-RD-04, an investigational gene therapy for cystinosis, and Phase 2 study of AVR-RD-01 in Fabry disease.

Regenxbio Inc (NASDAQ: RGNX) will make poster presentation of interim data from the Phase 1/2 trial of its investigational gene therapy RGX-121 for the treatment of Mucopolysaccharidosis Type II. The presentation is scheduled for Wednesday.

ASCO 2020 Genitourinary Cancers Symposium Presentations

Exelixis, Inc. (NASDAQ: EXEL): Phase 1b data for cabozantinib and Roche Holdings AG Basel ADR Common Stock's (OTC: RHHBY) Tecentriq in solid tumors (Thursday)

Advaxis, Inc. (NASDAQ: ADXS): Phase 1/2 data for ADXS-PSA and Merck's Keytruda from the KEYNOTE-046 study in castrate-resistant prostate cancer (Thursday)

TrovaGene Inc (NASDAQ: TROV): new Phase 2 data for onvansertib and zytiga in prostate cancer (Thursday)

Corvus Pharmaceuticals Inc (NASDAQ: CRVS): updated Phase 1b/2 data for CPI-444 in solid tumors

See Also: 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market

Monday

Tuesday

Thursday

Friday

Revolution Medicines, a biotech developing targeted cancer therapies using RAS pathway inhibitors, has filed to offer 10 million shares in an IPO, which is expected to be priced between $14 and $16. The company expects its shares to be listed on the Nasdaq under the ticker symbol "RVMD."

IPO Quiet Period Expiry

I-Mab (NASDAQ: IMAB)

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the rest here:
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight - Benzinga

Comments are closed.